Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida, Jiro Mukai, Kenji Furukawa, Seitaro Ohtsu, . . . Naoto Uemura. (2021). A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19. Wiley.
Chicago Style (17th ed.) CitationJunsaku Kitagawa, et al. A Phase I Study of High Dose Camostat Mesylate in Healthy Adults Provides a Rationale to Repurpose the TMPRSS2 Inhibitor for the Treatment of COVID‐19. Wiley, 2021.
MLA (9th ed.) CitationJunsaku Kitagawa, et al. A Phase I Study of High Dose Camostat Mesylate in Healthy Adults Provides a Rationale to Repurpose the TMPRSS2 Inhibitor for the Treatment of COVID‐19. Wiley, 2021.
Warning: These citations may not always be 100% accurate.